Difference between revisions of "European Federation of Pharmaceutical Industries and Associations"
Mira Purska (talk | contribs) |
m (badge) |
||
| (7 intermediate revisions by 3 users not shown) | |||
| Line 1: | Line 1: | ||
| − | EFPIA claims to represent the pharmaceutical industry operating in Europe being 'the voice on the EU scene of 2,100 companies committed to researching, developing and bringing to patients new medicines that improve health and the quality of life around the world'.<ref>http://http://www.efpia.org/Content/Default.asp</ref> It is based in Brussels and its mission is to 'to improve the competitiveness of the research-based pharmaceutical industry in Europe in a regulatory and political environment, which above all stimulates R&D and rewards innovation.'<ref>http://www.efpia.org/content/default.asp?PageID=90</ref> | + | {{Template:Pharma_Portal_badge}} |
| + | The '''European Federation of Pharmaceutical Industries and Associations'''(EFPIA) claims to represent the pharmaceutical industry operating in Europe being 'the voice on the EU scene of 2,100 companies committed to researching, developing and bringing to patients new medicines that improve health and the quality of life around the world'.<ref>http://http://www.efpia.org/Content/Default.asp</ref> It is based in Brussels and its mission is to 'to improve the competitiveness of the research-based pharmaceutical industry in Europe in a regulatory and political environment, which above all stimulates R&D and rewards innovation.'<ref>http://www.efpia.org/content/default.asp?PageID=90</ref> | ||
| − | In 2007 27 European Union member states signed the Innovative Medicines Initiative. This alliance between the European Commission and the | + | In 2007, 27 European Union member states signed the [[Innovative Medicines Initiative]]. This alliance between the European Commission and the EFPIA has a budget of 2.0 billion euros ($2.94 billion) over a seven-year period aimed at 'giving a boost to the EU's competitiveness in biomedical innovation'. The EC and the EFPIA contribute each 1.0 billion euros. The Commission's funds are to be dedicated exclusively to public-sector participants and smaller firms while the EFPIA's members will provide private-sector investment.<ref>[IMI to be adopted by 27 EU states] Pharma Marketletter, December 14, 2007</ref> |
| − | [[Johnson & Johnson]], [[Pfizer]], [[Novartis]] and [[Procter & Gamble]] were reported to plan launching the European Patient Information Channel, a pan-European television channel to promote prescription medicine information direct to the public. The funding | + | [[Johnson & Johnson]], [[Pfizer]], [[Novartis]] and [[Procter & Gamble]] were reported to plan launching the [[European Patient Information Channel]], a pan-European television channel to promote prescription medicine information direct to the public (at present direct-to-consumer advertising of prescription drugs is not permitted in Europe). The funding for this should come from the industry, with a board of medical, pharmaceutical and patient representatives. |
| − | + | According to the Guardian this idea was supported by [[European Patients' Forum]], an umbrella group with indirect links to drugmakers, but others are less enthusiastic. The [[International Society of Drug Bulletins]] told the newspaper that "pharmaceuticals companies' messages are focused on relatively few top sellers, exaggerating effects and concealing risk, confusing patients and putting pressure on doctors to prescribe drugs that they would not use otherwise."<ref>''European pharma television channel coming soon?'' Pharma Marketletter, May 23, 2007</ref> | |
| − | EFPIA denied any connection to this project saying it was a pilot to explore a form of interaction between drug firms and patients | + | EFPIA denied any connection to this project saying it was a pilot to explore a form of interaction between drug firms and patients. [[ABPI]] stressed that the pharmaceutical industry, while pressing for liberalization of information for the sector, was not seeking to advertise its products to the public. <ref>''European pharma television channel coming soon?'' Pharma Marketletter, May 23, 2007</ref> |
==Membership== | ==Membership== | ||
| − | [[Fachverband der Chemischen Industrie Österreichs]] (Austria) | + | *[[Fachverband der Chemischen Industrie Österreichs]] (Austria) |
| − | + | *[[Association Générale de l’Industrie du Médicament]] (Belgium) | |
| − | [[Association Générale de l’Industrie du Médicament]] (Belgium) | + | *[[Laegemiddelindustriforeningen the Danish Association of the Pharmaceutical Industry]] (Denmark) |
| − | + | *[[Lääketeollisuus ry Pharma Industry]] (Finland) | |
| − | [[Laegemiddelindustriforeningen the Danish Association of the Pharmaceutical Industry]] (Denmark) | + | *[[Les Entreprises du Médicament]] (France) |
| − | + | *[[Verband Forschender Arzneimittelhersteller]] (Germany) | |
| − | [[Lääketeollisuus ry Pharma Industry]] (Finland) | + | *[[Hellenic Association of Pharmaceutical Companies]] (Greece) |
| − | + | *[[Irish Pharmaceutical Healthcare Association]] (Ireland) | |
| − | [[Les Entreprises du Médicament]] (France) | + | *[[Associazione delle imprese del farmaco]] (Italy) |
| − | + | *[[Vereniging Innovatieve Geneesmiddelen Nederland]] (Netherlands) | |
| − | [[Verband Forschender Arzneimittelhersteller]] (Germany) | + | *[[Legemiddelindustriforeningen Norwegian Association of Pharmaceutical Manufacturers]] (Norway) |
| − | + | *[[Employers Union of Innovative Pharmaceutical Companies]] (Poland) | |
| − | [[Hellenic Association of Pharmaceutical Companies]] (Greece) | + | *[[Associação Portuguesa da Indústria Farmacêutica]] (Portugal) |
| − | + | *[[Asociación Nacional Empresarial de la Industria Farmacéutica]] (Spain) | |
| − | [[Irish Pharmaceutical Healthcare Association]] (Ireland) | + | *[[Läkemedelsindustriföreningen The Swedish Association of the Pharmaceutical Industry]] (Sweden) |
| − | + | *[[Société Suisse des Industries Chimiques]] (Switzerland) | |
| − | [[Associazione delle imprese del farmaco]] (Italy) | + | *[[Arastirmaci Ilac Firmalari Dernegi]] (Turkey) |
| − | + | *[[The Association of the British Pharmaceutical Industry]] (UK) | |
| − | [[Vereniging Innovatieve Geneesmiddelen Nederland]] (Netherlands) | + | *[[Bundesverband der Pharmazeutischen Industrie]] (Founder Member) |
| − | |||
| − | [[Legemiddelindustriforeningen Norwegian Association of Pharmaceutical Manufacturers]] (Norway) | ||
| − | |||
| − | [[Employers Union of Innovative Pharmaceutical Companies]] (Poland) | ||
| − | |||
| − | [[Associação Portuguesa da Indústria Farmacêutica]] (Portugal) | ||
| − | |||
| − | [[Asociación Nacional Empresarial de la Industria Farmacéutica]] (Spain) | ||
| − | |||
| − | [[Läkemedelsindustriföreningen The Swedish Association of the Pharmaceutical Industry]] (Sweden) | ||
| − | |||
| − | [[Société Suisse des Industries Chimiques]] (Switzerland) | ||
| − | |||
| − | [[Arastirmaci Ilac Firmalari Dernegi]] (Turkey) | ||
| − | |||
| − | [[The Association of the British Pharmaceutical Industry]] (UK) | ||
| − | |||
| − | [[Bundesverband der Pharmazeutischen Industrie]] (Founder Member) | ||
==People== | ==People== | ||
| Line 65: | Line 48: | ||
*[[Ann Robins]] Manager, Legal Affairs | *[[Ann Robins]] Manager, Legal Affairs | ||
*[[Christine-Lise Julou]] Manager, Scientific, Technical & Regulatory Affairs | *[[Christine-Lise Julou]] Manager, Scientific, Technical & Regulatory Affairs | ||
| + | |||
| + | ==External Resources== | ||
| + | *The Alliance for Lobbying Transparency and Ethics Regulation (ALTER-EU) [http://www.alter-eu.org/documents/2011/06/22/the-missing-millions-of-the-lobby-register The missing millions – how the new lobby register needs to tackle the 'under-reporting' by industry lobby groups], published 22 June 2011. Outlines under-reporting of lobby expenditure by a significant number of groups. | ||
| + | |||
===References=== | ===References=== | ||
<references/> | <references/> | ||
[[Category:Pharma Lobby Groups]] | [[Category:Pharma Lobby Groups]] | ||
Latest revision as of 15:39, 23 June 2011
|
This article is part of the Pharma_Portal project of Spinwatch. |
The European Federation of Pharmaceutical Industries and Associations(EFPIA) claims to represent the pharmaceutical industry operating in Europe being 'the voice on the EU scene of 2,100 companies committed to researching, developing and bringing to patients new medicines that improve health and the quality of life around the world'.[1] It is based in Brussels and its mission is to 'to improve the competitiveness of the research-based pharmaceutical industry in Europe in a regulatory and political environment, which above all stimulates R&D and rewards innovation.'[2]
In 2007, 27 European Union member states signed the Innovative Medicines Initiative. This alliance between the European Commission and the EFPIA has a budget of 2.0 billion euros ($2.94 billion) over a seven-year period aimed at 'giving a boost to the EU's competitiveness in biomedical innovation'. The EC and the EFPIA contribute each 1.0 billion euros. The Commission's funds are to be dedicated exclusively to public-sector participants and smaller firms while the EFPIA's members will provide private-sector investment.[3]
Johnson & Johnson, Pfizer, Novartis and Procter & Gamble were reported to plan launching the European Patient Information Channel, a pan-European television channel to promote prescription medicine information direct to the public (at present direct-to-consumer advertising of prescription drugs is not permitted in Europe). The funding for this should come from the industry, with a board of medical, pharmaceutical and patient representatives.
According to the Guardian this idea was supported by European Patients' Forum, an umbrella group with indirect links to drugmakers, but others are less enthusiastic. The International Society of Drug Bulletins told the newspaper that "pharmaceuticals companies' messages are focused on relatively few top sellers, exaggerating effects and concealing risk, confusing patients and putting pressure on doctors to prescribe drugs that they would not use otherwise."[4]
EFPIA denied any connection to this project saying it was a pilot to explore a form of interaction between drug firms and patients. ABPI stressed that the pharmaceutical industry, while pressing for liberalization of information for the sector, was not seeking to advertise its products to the public. [5]
Membership
- Fachverband der Chemischen Industrie Österreichs (Austria)
- Association Générale de l’Industrie du Médicament (Belgium)
- Laegemiddelindustriforeningen the Danish Association of the Pharmaceutical Industry (Denmark)
- Lääketeollisuus ry Pharma Industry (Finland)
- Les Entreprises du Médicament (France)
- Verband Forschender Arzneimittelhersteller (Germany)
- Hellenic Association of Pharmaceutical Companies (Greece)
- Irish Pharmaceutical Healthcare Association (Ireland)
- Associazione delle imprese del farmaco (Italy)
- Vereniging Innovatieve Geneesmiddelen Nederland (Netherlands)
- Legemiddelindustriforeningen Norwegian Association of Pharmaceutical Manufacturers (Norway)
- Employers Union of Innovative Pharmaceutical Companies (Poland)
- Associação Portuguesa da Indústria Farmacêutica (Portugal)
- Asociación Nacional Empresarial de la Industria Farmacéutica (Spain)
- Läkemedelsindustriföreningen The Swedish Association of the Pharmaceutical Industry (Sweden)
- Société Suisse des Industries Chimiques (Switzerland)
- Arastirmaci Ilac Firmalari Dernegi (Turkey)
- The Association of the British Pharmaceutical Industry (UK)
- Bundesverband der Pharmazeutischen Industrie (Founder Member)
People
- Arthur Higgins President
- Tom McKiIIop
- Brian Ager Director General
- Marie-Claire Pickaert Deputy Director General
- Andreas Preising Manager, Government Affairs
- Chantal Porges Director, Communication & Partnerships
- Magdalena Rodriguez de Azero Executive Manager, European Vaccine Manufacturers (EVM)
- Emmanuel Chantelot Executive Manager, European Biopharmaceutical Enterprises (EBE)
- Christine-Lise Julou Manager, Scientific, Technical & Regulatory Affairs
- Karen Strandgaard Manager, Research Directors Group
- Louis-Nicolas Fortin Manager, External Trade
- Brendan Barnes Manager, Multilateral Affairs
- Magda Chlebus Manager, CEE Region Affairs
- Ann Robins Manager, Legal Affairs
- Christine-Lise Julou Manager, Scientific, Technical & Regulatory Affairs
External Resources
- The Alliance for Lobbying Transparency and Ethics Regulation (ALTER-EU) The missing millions – how the new lobby register needs to tackle the 'under-reporting' by industry lobby groups, published 22 June 2011. Outlines under-reporting of lobby expenditure by a significant number of groups.
References
- ↑ http://http://www.efpia.org/Content/Default.asp
- ↑ http://www.efpia.org/content/default.asp?PageID=90
- ↑ [IMI to be adopted by 27 EU states] Pharma Marketletter, December 14, 2007
- ↑ European pharma television channel coming soon? Pharma Marketletter, May 23, 2007
- ↑ European pharma television channel coming soon? Pharma Marketletter, May 23, 2007
